A Phase III Multicenter Study of Valganciclovir for the Prevention of Late Cytomegalovirus Infection After Allogenic Hematopoietic Stem Cell Transplantation.

Trial Profile

A Phase III Multicenter Study of Valganciclovir for the Prevention of Late Cytomegalovirus Infection After Allogenic Hematopoietic Stem Cell Transplantation.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2015

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Cytomegalic inclusion disorders
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 19 Apr 2011 Actual patient numbers reported as 20 by the ClinicalTrials.gov record
    • 19 Apr 2011 Actual patient numbers reported as 20 by the ClinicalTrials.gov record
    • 15 Sep 2009 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov (NCT00275665).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top